Antidote-controlled modulation of factor IXa activity with the first-in-class REG1 anticoagulation system: A randomized phase 1 repeat dose safety and antidote dose-escalation study
Publication
, Conference
Chan, M; Alexander, JH; Rusconi, CP; Tonkens, RM; Harrington, RA; Becker, RC
Published in: CIRCULATION
October 16, 2007
Duke Scholars
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 16, 2007
Volume
116
Issue
16
Start / End Page
323 / 323
Location
Orlando, FL
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
80th Annual Scientific Session of the American-Heart-Association
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Chan, M., Alexander, J. H., Rusconi, C. P., Tonkens, R. M., Harrington, R. A., & Becker, R. C. (2007). Antidote-controlled modulation of factor IXa activity with the first-in-class REG1 anticoagulation system: A randomized phase 1 repeat dose safety and antidote dose-escalation study. In CIRCULATION (Vol. 116, pp. 323–323). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS.
Chan, Mark, John H. Alexander, Christopher P. Rusconi, Ross M. Tonkens, Robert A. Harrington, and Richard C. Becker. “Antidote-controlled modulation of factor IXa activity with the first-in-class REG1 anticoagulation system: A randomized phase 1 repeat dose safety and antidote dose-escalation study.” In CIRCULATION, 116:323–323. LIPPINCOTT WILLIAMS & WILKINS, 2007.
Chan M, Alexander JH, Rusconi CP, Tonkens RM, Harrington RA, Becker RC. Antidote-controlled modulation of factor IXa activity with the first-in-class REG1 anticoagulation system: A randomized phase 1 repeat dose safety and antidote dose-escalation study. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2007. p. 323–323.
Chan, Mark, et al. “Antidote-controlled modulation of factor IXa activity with the first-in-class REG1 anticoagulation system: A randomized phase 1 repeat dose safety and antidote dose-escalation study.” CIRCULATION, vol. 116, no. 16, LIPPINCOTT WILLIAMS & WILKINS, 2007, pp. 323–323.
Chan M, Alexander JH, Rusconi CP, Tonkens RM, Harrington RA, Becker RC. Antidote-controlled modulation of factor IXa activity with the first-in-class REG1 anticoagulation system: A randomized phase 1 repeat dose safety and antidote dose-escalation study. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2007. p. 323–323.
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 16, 2007
Volume
116
Issue
16
Start / End Page
323 / 323
Location
Orlando, FL
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
80th Annual Scientific Session of the American-Heart-Association
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology